

## TOWARDS THE IMPLEMENTATION OF A CONTINUOUS BIOPROCESS IN SINGLE USE TECHNOLOGY

Jorgen Magnus, Bayer  
jorgen.magnus@bayer.com  
Maïke Temming, Bayer  
Peter Schwan, Bayer  
Viktorija Kistler, Bayer  
Martin Lobedann, Invite GmbH  
Stefan Sievers, Bayer  
Martin Poggel, Bayer  
Thomas Daszkowski, Bayer

Key Words: Monoclonal antibodies, continuous processing, single use, process control, downstream

Bayer has developed a new production technology for monoclonal antibodies based on single use equipment and continuous processing. The development is referred to as the MoBiDiK project (Modular, Biologics, Disposable and Continuous) and was presented at the ICB 1 and ICB 2 conferences. At the ICB 3 conference we will focus on the topics that are critical to the implementation of the technology in a GMP production environment. These are: Process robustness, GMP readiness of the equipment, automation as well as process control and product release strategies.